Discover Fragile X Syndrome (FXS)- the causes, symptoms, diagnosis, and treatment options. Learn about FXS signs, care tips, ...
Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare genetic disease. The French pharma is offering as much as $450 ...
Harmony also touts late-stage asset EPX-100 (clemizole hydrochloride), which the biotech is running through a pair of phase 3 trials in Dravet syndrome and Lennox-Gastaut Syndrome— both rare forms of ...
Studies of mouse models of Fragile X syndrome and Phelan-McDermid syndrome show that treatment with cannabidiol (CBD) and the diabetes drug metformin can alleviate behavioral difficulties, according ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Quiver Bioscience (“Quiver”) and QurAlis Corporation (“QurAlis”), today announced that the companies have entered into a research collaboration to advance a novel ...
NEW YORK (Reuters Health) - L-acetylcarnitine (LAC), a natural substance devoid of side effects, may be considered an alternative to stimulants to control attention deficit hyperactivity disorder ...
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback